{"classes":[{"categories":[{"measurements":[{"comment":"NA: total volume of excreted urine was not recorded. Thus, no % of urinary excretion could be calculated.","groupId":"OG000","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Urine samples were collected for activity-based pharmacokinetics characterization in the dosimetry group. Vd was to be listed and summarized using descriptive statistics.","dispersionType":"Standard Deviation","groups":[{"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"OG000","title":"Breast"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (FAS). Dosimetry group targeted participants with Breast Cancer and Prostate Cancer, but only 2 participants from Breast Cancer arm enrolled in the Dosimetry Group. As the total volume of excreted urine was not recorded, no percentage of urinary excretion could be calculated.","reportingStatus":"POSTED","timeFrame":"[68Ga]-NeoBOMB1 PET imaging acquired at Day 1","title":"Dosimetry Group: Urinary Excretion of [68Ga]-NeoBOMB1 (Vd)","type":"SECONDARY","unitOfMeasure":"L"}